This morning we read about Novo Nordisk spending over $100 to expand their manufacturing facilities in Denmark. This comes after Novo bought an existing facility in North Carolina to expand capacity here in the US. Lilly has also been on a spending spree as has Abbott and Dexcom. While this isn’t big news it does point to an often-overlooked hurdle faced by every company seeking to enter the crowded diabetes market. The ability to manufacture products on a massive scale.
Unlike other consumer products diabetes products whether they are drugs or devices are regulated by the FDA . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.